Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$5.89 USD
+0.78 (15.26%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.77 -0.12 (-2.04%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Black Diamond Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 131 | 123 | 210 | 315 | 155 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 5 | 6 | 4 | 1 |
Total Current Assets | 134 | 128 | 216 | 320 | 156 |
Net Property & Equipment | 2 | 3 | 3 | 0 | 0 |
Investments & Advances | 1 | 1 | 1 | 1 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 2 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 159 | 156 | 248 | 330 | 158 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 4 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 17 | 13 | 20 | 12 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 20 | 15 | 24 | 14 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 201 |
Total Liabilities | 42 | 41 | 52 | 22 | 205 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 534 | 453 | 440 | 425 | 4 |
Retained Earnings | -417 | -335 | -244 | -118 | -51 |
Other Equity | 0 | -2 | 0 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 117 | 116 | 196 | 308 | -47 |
Total Liabilities & Shareholder's Equity | 159 | 156 | 248 | 330 | 158 |
Total Common Equity | 117 | 116 | 196 | 308 | -47 |
Shares Outstanding | 51.60 | 36.30 | 36.20 | 36.10 | 32.60 |
Book Value Per Share | 2.26 | 3.19 | 5.41 | 8.53 | -1.45 |
Fiscal Year End for Black Diamond Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 131 | 144 | 90 | 103 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 3 | 3 | 5 |
Total Current Assets | NA | 134 | 147 | 93 | 108 |
Net Property & Equipment | NA | 2 | 2 | 2 | 2 |
Investments & Advances | NA | 1 | 1 | 1 | 1 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 159 | 172 | 120 | 136 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 3 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 17 | 14 | 11 | 10 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 20 | 15 | 14 | 13 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 42 | 38 | 38 | 37 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 534 | 533 | 458 | 455 |
Retained Earnings | NA | -417 | -398 | -375 | -356 |
Other Equity | NA | 0 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 117 | 134 | 82 | 98 |
Total Liabilities & Shareholder's Equity | NA | 159 | 172 | 120 | 136 |
Total Common Equity | 0 | 117 | 134 | 82 | 98 |
Shares Outstanding | 51.70 | 51.60 | 51.60 | 36.50 | 36.50 |
Book Value Per Share | 0.00 | 2.26 | 2.60 | 2.25 | 2.69 |